Ulthera, Inc., a global, growth-stage medical device company, announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area, or décolletage. The Ulthera System combines ultrasound imaging with focused ultrasound therapy in a procedure known as Ultherapy, and it has been used in many Asian countries to treat the face and neck since 2008. The new décolletage indication will utilize the System's same technology to encourage the natural formation of collagen and elastin on the chest, helping to lift tissue. For the décolletage, this lifting effect can result in a gradual reduction of chest wrinkles over three months, with continued improvement possible for up to six months post-procedure, according to the company. The Ulthera System is cleared by the US FDA for use in a non-invasive treatment of the face to lift the eyebrow for a desired aesthetic effect. The new clinical indication to treat the décolletage will not be commercially available in all Asian countries, including those that do not currently offer Ultherapy, as well as Singapore and Hong Kong, where the System is only cleared to treat the face.